

Faceted Search Guide


Cortellis HTA Intelligence

Quickly find HTA Reimbursement, Managed Entry Agreement and Label events from 21 markets and 5 Regulatory Authorities using Faceted Search in Cortellis HTA Intelligence.

In **Faceted Search** you can use filters to quickly drill down to the HTA events of interest to you using 39 distinct filters.

Example: Find Non-small-cell lung cancer Drugs with a Decision of Recommended from agency G-BA where the Reason for decision was Greater efficacy/effectiveness.

1. **Click the Search tab** in the ribbon at the top of the page, then select your search parameters from the menu on the left side of the page.
2. **Select Event Type “Reimbursement”**. Applied filters update the results automatically.
3. In the **Disease Condition menu select Non-small-cell Lung Cancer**. Scroll through the list or begin typing for suggestions.



Clarivate

Cortellis HTA Intelligence

Home Diseases Drugs Countries Companies **Search**

Clear Search Parameters

Data Depth (1)

Event Type (3)

Managed Entry Agreement

Label

Reimbursement

Disease Condition (85)

Non-small-cell Lung Cancer

Search

Drug Name (357)

Search

Brand Name (622)

Search

Country / Region (18)

Search


Showing 100 of 1397 Results

Export to Excel Save Search


Status	Date	Country / Region	Disease Conditions	Brand Name	Drug Name	Manufacturer	Contract Type	Key Metric	PDF	Add
	05/2022	United Kingdom	Non-small-cell Lung Cancer	Tepmetoko, Tepmetoko	tepotinib	Merck & Co., Inc.	Financially based	Price reduction		
	04/2022	United Kingdom	Breast Cancer	Hercion, Herceptin, Ontruzant, Karsinti, Herizuma, Trazimera, Herceptin SC, Zercepac	trastuzumab	Seagen B.V.	Financially based	Price reduction		
	04/2022	United Kingdom	Breast Cancer	Tukysa	tucatinib	Seagen B.V.	Financially based	Price reduction		
	04/2022	United Kingdom	Ovarian Cancer	Zejula	niraparib	GlaxoSmithKline (GSK)	Financially based	Price reduction		
	04/2022	United Kingdom	Multiple Myeloma	Darzalex, Darinvi	daratumumab	Janssen Biotech Inc.	Financially based	Price reduction		
	02/2022	United Kingdom	Hodgkin's Lymphoma	Keytruda	pembrolizumab	Merck Sharp & Dohme Corp. (MSD)	Financially based	Price reduction		
	02/2022	United Kingdom	Non-small-cell Lung Cancer	Keytruda	pembrolizumab	Merck Sharp & Dohme Corp. (MSD)	Financially based	Price reduction		
	02/2022	United Kingdom	Melanoma	Keytruda	pembrolizumab	Merck Sharp & Dohme Corp. (MSD)	Financially based	Price reduction		
	02/2022	United Kingdom	Acute Myeloid Leukemia	Venclexta, Venclyxto	venetoclax	Abbvie Inc.	Financially based	Price reduction		
	02/2022	United Kingdom	Migraines	Ajovy	fremanezumab	Teva Pharm Industries	Financially based	Price reduction		

Results update as you continue to add more filters.

4. Scroll down and Under the **Agency** menu select **G-BA**.



5. In the **Reason for decision (clinical)** menu select **Greater efficacy/effectiveness**.



6. Your **Search Result List** should look like this:

Click entries to reveal more details on the decisions.

Export your results to Excel or Save your search.

Clear Search Parameters

Data Depth 1

Event Type (1)

Reimbursement

Disease Condition (43)

Search

Non-small-cell Lung Cancer x

Therapeutic Area (2)

Oncology

Oncology - Solid Tumor

Stage of Cancer (4)

Advanced

Locally advanced

Metastatic

Unresectable





















Biomarkers Indicated (7)

Search

Drug Name (10)

Search

Showing 16 of 16 Results

Status	Date	Disease Condition	Agency	Decision	Drug Name	Brand Name	Manufacturer	Line of therapy	PDF	Add
●	10/2020	Non-small-cell Lung Cancer	G-BA	Recommend	brigatinib	Alunbrig	Takeda Oncology	1+		
●	10/2020	Non-small-cell Lung Cancer	G-BA	Recommend	brigatinib	Alunbrig	Takeda Oncology	1+		
●	09/2019	Non-small-cell Lung Cancer	G-BA	Recommend	pembrolizumab	Keytruda	Merck & Co., Inc.	1		
●	09/2019	Non-small-cell Lung Cancer	G-BA	Recommend	pembrolizumab	Keytruda	Merck & Co., Inc.	1		
<div style="border: 1px solid #ccc; padding: 5px;"> <p>Decision reason - clinical (details)</p> <p>There is an indication of a considerable additional benefit over the appropriate comparator.</p> <p>Indication</p> <p>As monotherapy for the first-line treatment of adults with metastatic NSCLC who have PD-L1-expressing tumors (Tumour Proportion Score of $\geq 50\%$) without EGFR- or ALK-positive tumor mutations.</p> <p>Additional Benefit (G-BA)</p> <p>Considerable additional benefit</p> </div>										
●	03/2018	Non-small-cell Lung Cancer	G-BA	Recommend	atezolizumab	Tecentriq	Roche Holding AG	2+		
●	10/2017	Non-small-cell Lung Cancer	G-BA	Recommend	alectinib	Alecensa	Genentech, USA Inc.	2		
●	10/2017	Non-small-cell Lung Cancer	G-BA	Recommend with restrictions	osimertinib	Tagrisso	AstraZeneca	2		
●	08/2017	Non-small-cell Lung Cancer	G-BA	Recommend	pembrolizumab	Keytruda	Merck & Co., Inc.	1		
●	03/2017	Non-small-cell Lung Cancer	G-BA	Recommend	ceritinib	Zykadia	Novartis AG	2+		
●	11/2015	Non-small-cell Lung Cancer	G-BA	Recommend with restrictions	afatinib	Giotrif	Boehringer Ingelheim	1		


Refine your search by adding more filters.

Click the PDF icons to view the source documents.

Click the Add to basket icon to compare details on up to 4 decisions in a table.

7. See your **Saved searches**:

Click on **your name**, and then on **Saved searches** tab to access your searches.



Click Description links to rerun.

Click to delete your saved search.

For more information contact Customer Service at **LS Product Support**